XML 23 R8.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net income (loss) $ 367,070 $ 355,757 $ (158,267)
Adjustments to reconcile net income (loss) to cash flows from operating activities:      
Depreciation and amortization 28,533 74,927 77,862
Share-based compensation expense 96,637 100,905 94,254
Deferred income taxes 40,522 (99,902) (32,795)
Change in the fair value of contingent consideration     21,750
Other non-cash charges 4,512 6,329 5,531
Changes in assets and liabilities:      
Receivables (52,052) (44,510) 25,250
Contract assets (4,284) 8,223 4,434
Inventory 3,091 (2,712) (31,021)
Prepaid expenses and other assets 2,254 (34,847) (5,328)
Right-of-use assets 7,215 15,387 16,569
Accounts payable and accrued expenses (57,967) 23,009 15,534
Accrued sales discounts, allowances and reserves 8,811 11,526 14,899
Contract liabilities (3,525) (5,926) (7,129)
Operating lease liabilities (10,123) (16,147) (33,225)
Other long-term liabilities 8,430 9,334 12,726
Cash flows provided by operating activities 439,124 401,353 21,044
CASH FLOWS FROM INVESTING ACTIVITIES:      
Additions of property, plant and equipment (33,484) (48,048) (38,255)
Proceeds from the sale of equipment 461 354  
Proceeds from contingent consideration     1,273
Return of Fountain Healthcare Partners II, L.P. investment 43   485
Proceeds from the sale of the Athlone Facility 97,933    
Purchases of investments (486,547) (254,471) (309,671)
Sales and maturities of investments 310,286 355,522 281,627
Cash flows (used in) provided by investing activities (111,308) 53,357 (64,541)
CASH FLOWS FROM FINANCING ACTIVITIES:      
Cash transferred to Mural Oncology plc at separation   (275,000)  
Proceeds from the issuance of ordinary shares under share-based compensation arrangements 27,572 16,760 19,630
Employee taxes paid related to net share settlement of equity awards (29,637) (28,474) (18,204)
Payment for the repurchase of ordinary shares (200,282)    
Prepayment of long-term debt (289,542)    
Principal payments of long-term debt (2,250) (3,000) (3,000)
Cash flows used in financing activities (494,139) (289,714) (1,574)
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS (166,323) 164,996 (45,071)
CASH AND CASH EQUIVALENTS—Beginning of period 457,469 292,473 337,544
CASH AND CASH EQUIVALENTS—End of period 291,146 457,469 292,473
SUPPLEMENTAL CASH FLOW DISCLOSURE:      
Cash paid for interest 23,010 22,748 13,563
Cash paid for taxes 2,592 44,243 20,749
Non-cash investing and financing activities:      
Purchased capital expenditures included in accounts payable and accrued expenses $ 2,254 $ 2,645 $ 2,950